Retatrutide TRIUMPH-2 in The Lancet: What the Full Phase 3 Paper Reports
TL;DR: The Lancet published retatrutide TRIUMPH-2 on 30 Sep 2026: an 80-week phase 3 trial of 1,152 adults with type 2 diabetes. Pharma data, not research use.
What Did The Lancet Publish on 30 September 2026?
On 30 September 2026, The Lancet published the full report of TRIUMPH-2, a Phase 3 trial of retatrutide in adults with obesity and type 2 diabetes, titled “Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial”.[1] The paper appeared as the data were presented at the European Association for the Study of Diabetes (EASD) annual meeting in Milan.[2] Trade press reported that the companion TRIUMPH-1 paper, covering adults without diabetes, was published the same day in the New England Journal of Medicine.[3]
Eli Lilly had already announced topline TRIUMPH-2 results on 23 July 2026; we covered that release in our TRIUMPH-2 and TRIUMPH-3 topline report. What is new this week is peer review: the methods, estimands and prespecified secondary endpoints are now in a citable journal article. Retatrutide is an investigational compound from a licensed pharmaceutical developer, and none of this reporting concerns research-use material.
How Was TRIUMPH-2 Designed?
Population: 1,152 adults with a mean BMI of 38.2 kg/m² and a mean HbA1c of 7.71%, on stable type 2 diabetes therapy that was largely oral agents.[4]
Arms: placebo, or retatrutide 4 mg, 9 mg or 12 mg once weekly (a GIP, GLP-1 and glucagon receptor agonist), assessed at 80 weeks.[4]
Registry: ClinicalTrials.gov NCT05929079
A triple-agonist mechanism is the reason the compound draws laboratory interest. For receptor-level background, see our retatrutide mechanism of action guide.
What Endpoints Did the Paper Report?
Trade coverage of the paper reported the following prespecified results at week 80, with body-weight change expressed under the treatment-regimen estimand:[4]
| Arm | Body-weight change (treatment-regimen) | Reported against |
|---|---|---|
| Placebo | −5.1% | Reference arm |
| Retatrutide 4 mg | −11.9% | P<0.0001 vs placebo |
| Retatrutide 9 mg | −16.8% | P<0.0001 vs placebo |
| Retatrutide 12 mg | −18.8% | P<0.0001 vs placebo |
Secondary glycaemic and cardiometabolic readouts were reported as HbA1c reductions of roughly 1.4 to 1.6 percentage points across retatrutide arms against 0.2 for placebo, and, at 12 mg, reductions of 39.5% in triglycerides, 19.6% in non-HDL cholesterol and 10.8 mm Hg in systolic blood pressure.[4] These are a sponsor-run trial’s outcomes in a clinical population; they are not performance claims for any research reagent.
Why Do Estimands Matter When Reading the Paper?
Lilly’s 23 July topline release put TRIUMPH-2 weight change at 12.7%, 19.1% and 20.8% for the three doses.[5] The Lancet figures above (11.9%, 16.8%, 18.8%) are lower, and the cause is analytic, not contradictory. The treatment-regimen estimand includes every randomised participant whatever happened to their treatment; an efficacy estimand describes outcomes while on treatment. They answer different questions, so a researcher comparing the topline and the paper should confirm which estimand each number uses before drawing any conclusion.
The same discipline applies across the programme. Our TRIUMPH-1 guide and type 2 diabetes guide list the other Phase 3 reports side by side.
What Safety Topics Do Reviewers Highlight?
Coverage of the EASD presentation flagged gastrointestinal events, hypotension and dysesthesia as the safety themes in the paper.[4] Dysesthesia, an altered-sensation event, was also a topic in the TRIUMPH-1 reporting; our dysesthesia explainer collects what has been published. Readers should consult the paper’s adverse-event tables directly rather than rely on summaries.
What Happens Next for Retatrutide?
| Track | Milestone | Timing |
|---|---|---|
| Eli Lilly | FDA Biologics License Application | Q1 2027 (company guidance)[5] |
| Remaining Phase 3 programmes | Further readouts | Per company guidance |
| Eli Lilly v. Kennedy | Seventh Circuit decision on classification | No date set |
See the retatrutide FDA approval timeline for the regulatory track.
How Does a Pharma Trial Relate to Research-Grade Retatrutide?
It does not transfer. A Phase 3 paper describes a specific investigational product, manufactured and controlled by the sponsor, studied under regulatory oversight. A research reagent is a different thing: its relevant properties are identity, purity and storage stability for in vitro work, documented per batch. See how to read a certificate of analysis and whether research peptides are legal in the UK.
Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA, HPRA or FDA. Not for human or veterinary consumption. See our Research Use Policy and MHRA Statement.
References
- The Lancet. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Published 30 September 2026. thelancet.com
- Healio. Retatrutide confers ‘substantial’ weight loss for adults with obesity, type 2 diabetes. 30 September 2026. healio.com
- NBC News. People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug (reporting the Lancet and NEJM publications). nbcnews.com
- Pharmacy Times. Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity. pharmacytimes.com; see also AJMC, ajmc.com. Registry: NCT05929079
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered substantial weight loss and A1C reduction in obesity and type 2 diabetes. Investor press release. investor.lilly.com; Q1 2027 filing guidance per BioPharma Dive
Frequently Asked Questions
What did The Lancet publish on 30 September 2026 about retatrutide?
The Lancet published 'Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial' on 30 September 2026, the day the data were presented at EASD in Milan. The trial (NCT05929079) randomised 1,152 adults to placebo or retatrutide 4, 9 or 12 mg once weekly for 80 weeks. Retatrutide is an investigational compound sponsored by Eli Lilly and is not approved by the MHRA, EMA or FDA.
What is the difference between the treatment-regimen and efficacy estimands?
The treatment-regimen estimand analyses all randomised participants regardless of whether they stayed on treatment, so it reflects the effect of being assigned to a regimen. The efficacy estimand analyses outcomes as if participants had stayed on treatment. The two answer different questions, so figures from Lilly's July topline release and the peer-reviewed paper should not be compared without checking which estimand each uses.
Does the TRIUMPH-2 paper apply to research-use retatrutide?
No. TRIUMPH-2 reports a licensed-pharma sponsor's clinical trial of a specific investigational formulation under regulatory oversight. Velox Peptides supplies retatrutide only as an HPLC-verified in vitro research reagent, not a medicine, and nothing in the trial constitutes guidance for any use outside laboratory research.
Where can I read the primary sources?
The Lancet abstract, the ClinicalTrials.gov record NCT05929079 and Eli Lilly's investor press releases are linked in the reference list. This article is third-party reporting and does not replace reading the paper itself.